06 September 2013

Bayer HealthCare Opens New Laboratory in Auckland, New Zealand

Leverkusen/Auckland – 06 September 2013 – Bayer HealthCare is increasing the research in Animal Health with expanded capacity at its Centre for Innovation and Development (CID) in Auckland, New Zealand. A new laboratory will expedite international research into the health and wellness of both farm and companion animals. The facility will focus on making animal medicines more effective by developing new formulations, and is staffed with a global team of 35 experts, analysts and technicians.

The Bayer HealthCare Centre for Innovation and Development in New Zealand is responsible for important contributions to the animal health field, especially in the areas of mastitis control, reproduction and metabolic health management. 

“In the past year, this site has generated Tylofen, the first mastitis treatment to be combined with pain relief to support both the wellness and welfare of dairy herds,” said Derek Bartlett, Country Division Head of Bayer HealthCare, Animal Health, New Zealand. “And in the pet care segment, the launch of Hyper-T, a transdermal treatment for hyperthyroidism in cats has saved both owners and cats the daily stress of tablet administration.”

This new laboratory represents Bayer’s continued commitment to developing new veterinary solutions,” explains Dr. Douglas Hutchens, Chief Veterinary Officer and Head of Global Development for Bayer HealthCare’s Animal Health Division. 

The Bayer Group is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 18.6 billion (2012), is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. Bayer HealthCare has a global workforce of 55,300 employees (Dec 31, 2012) and is represented in more than 100 countries. 

Source: Bayer